BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Goswami P, Joshi N, Singh S. Neurodegenerative signaling factors and mechanisms in Parkinson's pathology. Toxicol In Vitro 2017;43:104-12. [PMID: 28627426 DOI: 10.1016/j.tiv.2017.06.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Joshi N, Singh S. Updates on immunity and inflammation in Parkinson disease pathology. Journal of Neuroscience Research 2018;96:379-90. [DOI: 10.1002/jnr.24185] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
2 Silva AR, Grosso C, Delerue-Matos C, Rocha JM. Comprehensive review on the interaction between natural compounds and brain receptors: Benefits and toxicity. Eur J Med Chem 2019;174:87-115. [PMID: 31029947 DOI: 10.1016/j.ejmech.2019.04.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
3 Du B, Xue Q, Liang C, Fan C, Liang M, Zhang Y, Bi X, Hou L. Association between alpha-synuclein (SNCA) rs11931074 variability and susceptibility to Parkinson's disease: an updated meta-analysis of 41,811 patients. Neurol Sci 2020;41:271-80. [PMID: 31758346 DOI: 10.1007/s10072-019-04107-8] [Reference Citation Analysis]
4 Hu K, Chen X, Chen W, Zhang L, Li J, Ye J, Zhang Y, Zhang L, Li CH, Yin L, Guan YQ. Neuroprotective effect of gold nanoparticles composites in Parkinson's disease model. Nanomedicine 2018;14:1123-36. [PMID: 29474924 DOI: 10.1016/j.nano.2018.01.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 9.8] [Reference Citation Analysis]
5 Rahman AA, Morrison BE. Contributions of VPS35 Mutations to Parkinson's Disease. Neuroscience 2019;401:1-10. [PMID: 30660673 DOI: 10.1016/j.neuroscience.2019.01.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
6 Ogura H, Hatip-Al-Khatib I, Suenaga M, Hatip FB, Mishima T, Fujioka S, Ouma S, Matsunaga Y, Tsuboi Y. Circulatory 25(OH)D and 1,25(OH)2D as differential biomarkers between multiple system atrophy and Parkinson's disease patients. eNeurologicalSci 2021;25:100369. [PMID: 34611554 DOI: 10.1016/j.ensci.2021.100369] [Reference Citation Analysis]
7 Rodríguez-Cruz A, Romo-Mancillas A, Mendiola-Precoma J, Escobar-Cabrera JE, García-Alcocer G, Berumen LC. "Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson's disease". IBRO Rep 2020;8:28-35. [PMID: 31909290 DOI: 10.1016/j.ibror.2019.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y. Benefits of Vitamins in the Treatment of Parkinson's Disease. Oxid Med Cell Longev 2019;2019:9426867. [PMID: 30915197 DOI: 10.1155/2019/9426867] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
9 Wi R, Chung YC, Jin BK. Functional Crosstalk between CB and TRPV1 Receptors Protects Nigrostriatal Dopaminergic Neurons in the MPTP Model of Parkinson's Disease. J Immunol Res 2020;2020:5093493. [PMID: 33062722 DOI: 10.1155/2020/5093493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Lachén-Montes M, González-Morales A, Iloro I, Elortza F, Ferrer I, Gveric D, Fernández-Irigoyen J, Santamaría E. Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling. Neurobiol Aging 2019;73:123-34. [PMID: 30342273 DOI: 10.1016/j.neurobiolaging.2018.09.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
11 Li D, Song X, Huang H, Huang H, Ye Z. Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α. Neurosci Lett 2018;683:181-4. [PMID: 30063943 DOI: 10.1016/j.neulet.2018.07.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
12 Song MK, Lee JH, Kim J, Kim JH, Hwang S, Kim YS, Kim YJ. Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model. Neurosci Lett 2021;740:135425. [PMID: 33075422 DOI: 10.1016/j.neulet.2020.135425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Imbriani P, Schirinzi T, Meringolo M, Mercuri NB, Pisani A. Centrality of Early Synaptopathy in Parkinson's Disease. Front Neurol 2018;9:103. [PMID: 29545770 DOI: 10.3389/fneur.2018.00103] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
14 Lilli NL, Révy D, Robelet S, Lejeune B. Effect of the micro-immunotherapy medicine 2LPARK® on rat primary dopaminergic neurons after 6-OHDA injury: oxidative stress and survival evaluation in an in vitro model of Parkinson's disease. Degener Neurol Neuromuscul Dis 2019;9:79-88. [PMID: 31372089 DOI: 10.2147/DNND.S202966] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 de Oliveira MR. Carnosic Acid as a Promising Agent in Protecting Mitochondria of Brain Cells. Mol Neurobiol 2018;55:6687-99. [DOI: 10.1007/s12035-017-0842-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
16 Joshi H, Jha BK. Fractionally delineate the neuroprotective function of calbindin-D28k in Parkinson’s disease. Int J Biomath 2019;11:1850103. [DOI: 10.1142/s1793524518501036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
17 Petrovic S, Arsic A, Ristic-Medic D, Cvetkovic Z, Vucic V. Lipid Peroxidation and Antioxidant Supplementation in Neurodegenerative Diseases: A Review of Human Studies.Antioxidants (Basel). 2020;9:1128. [PMID: 33202952 DOI: 10.3390/antiox9111128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
18 Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, Rajasekaran R, Srikumar PS. Alpha-Synuclein Aggregation in Parkinson's Disease. Front Med (Lausanne) 2021;8:736978. [PMID: 34733860 DOI: 10.3389/fmed.2021.736978] [Reference Citation Analysis]
19 Singh A, Yadawa AK, Chaturvedi S, Wahajuddin M, Mishra A, Singh S. Mechanism for antiParkinsonian effect of resveratrol: Involvement of transporters, synaptic proteins, dendrite arborization, biochemical alterations, ER stress and apoptosis. Food Chem Toxicol 2021;155:112433. [PMID: 34302886 DOI: 10.1016/j.fct.2021.112433] [Reference Citation Analysis]
20 Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease. Ageing Res Rev 2018;45:53-61. [PMID: 29705121 DOI: 10.1016/j.arr.2018.04.004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 21.8] [Reference Citation Analysis]
21 Guo T, Chen L. Gut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights. Eur J Inflamm 2022;20:1721727X2210837. [DOI: 10.1177/1721727x221083763] [Reference Citation Analysis]
22 Li XX, Zhang F. Targeting TREM2 for Parkinson's Disease: Where to Go? Front Immunol 2021;12:795036. [PMID: 35003116 DOI: 10.3389/fimmu.2021.795036] [Reference Citation Analysis]
23 Nakajima A, Ohizumi Y. Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer's Disease and Parkinson's Disease. Int J Mol Sci 2019;20:E3380. [PMID: 31295812 DOI: 10.3390/ijms20143380] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
24 Hou Y, Li X, Liu C, Zhang M, Zhang X, Ge S, Zhao L. Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease. Exp Gerontol 2021;150:111376. [PMID: 33905875 DOI: 10.1016/j.exger.2021.111376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
25 Naseer A, Mir SS, Takacs-Vellai K, Nazir A. Sirtuins and Autophagy in Age-Associated Neurodegenerative Diseases: Lessons from the C. elegans Model. Int J Mol Sci 2021;22:12263. [PMID: 34830158 DOI: 10.3390/ijms222212263] [Reference Citation Analysis]
26 Kang Y, Kang X, Zhang H, Liu Q, Yang H, Fan W. Gut Microbiota and Parkinson's Disease: Implications for Faecal Microbiota Transplantation Therapy. ASN Neuro 2021;13:17590914211016217. [PMID: 34053243 DOI: 10.1177/17590914211016217] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
27 Li L, Lu J, Sun Y, Jin X. Acupuncture protects from 6-OHDA-induced neuronal damage by balancing the ratio of DMT1/Fpn1. Saudi J Biol Sci 2019;26:1948-55. [PMID: 31889778 DOI: 10.1016/j.sjbs.2019.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]